Опыт применения тримебутина малеата в режиме пролонгированной монотерапии у пациентов с синдромом раздраженного кишечника

2. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Алгоритм ведения пациентов с синдромом раздраженного кишечника. Римские критерии IV. РМЖ. 2017; 10: 718–22. / Maev I.V., Cheremushkin S.V., Kucheryavyj Yu.A., Cheremushkina N.V. Algoritm vedeniya pacientov s sindromom razdrazhennogo kishechnika. Rimskie kriterii IV. RMZh. 2017; 10: 718–22. [in Russian]
3. Stanghellini V, Chan FK, Hasler WL et al. Gastroduodenal Disorders. Gastroenterology 2016; 150 (6): 1380–92.
4. Маев И.В., Андреев Д.Н., Дичева Д.Т. и др. Функциональная диспепсия: современное состояние проблемы. Мед. вестн. МВД. 2013; 4: 38–45. / Maev I.V., Andreev D.N., Dicheva D.T. i dr. Funktsional'naya dispepsiya: sovremennoe sostoyanie problemy. Med. vestn. MVD. 2013; 4: 38–45. [in Russian]
5. Маев И.В., Дичева Д.Т., Щегланова М.П. и др. Функциональная диспепсия в свете Римских критериев IV пересмотра (2016). Гастроэнтерология (Прил. к журн. Consilium Medicum). 2016; 2: 5–10. / Maev I.V., Dicheva D.T., Shcheglanova M.P. et al. Functional dyspepsia in the context of the 2016 Rome IV updates. Consilium Medicum. Gastroenterology (Suppl.). 2016; 2: 5–10. [in Russian]
6. Persson R, Wensaas K-A, Hanevik K et al. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. BMC Gastroenterol 2015; 15: 66.
7. Perveen I, Rahman MM, Saha M et al. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol 2014; 33 (3): 265–73. DOI: 10.1007/s12664-014-0447-1
8. Symptom overlaps between functional heartburn, functional dyspepsia, and irritable bowel syndrome. Da Xue Xue Bao Yi Xue Ban. 2014; 45 (3): 489–92.
9. Kumagai H, Yokoyama K, Imagawa T, Yamagata T. Functional dyspepsia and irritable bowel syndrome in teenagers: Internet survey. Pediatr Int 2016; 58 (8): 714–20. DOI: 10.1111/ped.12884
10. Miwa H. Why dyspepsia can occur without organic disease: pathogenesis and management of functional dyspepsia. J Gastroenterol 2012; 47: 862–71.
11. Camilleri M, Tack JF. Current medical treatments of dyspepsia and irritable bowel syndrome. Gastroenterol Clin North Am 2010; 39: 481–93.
12. Маев И.В., Самсонов А.А., Андреев Д.Н. Современный алгоритм ведения пациентов с синдромом хронического запора с позиций внедрения новых фармакологических препаратов. Фарматека. 2012; 13: 37–43. / Maev I.V., Samsonov A.A., Andreev D.N. Sovremennyi algoritm vedeniya patsientov s sindromom khronicheskogo zapora s pozitsii vnedreniya novykh farmakologicheskikh preparatov. Farmateka. 2012; 13: 37–43. [in Russian]
13. Кучерявый Ю.А., Андреев Д.Н. Перспективы лечения кислотозависимых заболеваний. Клин. перспективы гастроэнтерологии, гепатологии. 2014; 2: 15–24. / Kucheryavyj Yu.A., Andreev D.N. Perspektivy lecheniya kislotozavisimyh zabolevanij. Klin. perspektivy gastroenterologii, gepatologii. 2014; 2: 15–24. [in Russian]
14. Garros A, Mion F, Marjoux S et al. Factors associated with nonresponse to proton pump inhibitors therapy in patients referred for esophageal pH-impedance monitoring. Dis Esophagus 2015.
15. Bitar KN, Makhlouf GM. Selective presence of opiate receptors on intestinal circular muscle cells. Life Sci 1985; 37: 1545–50.
16. Allescher HD, Ahmad S, Kostka P et al. Distribution of opioid receptors in canine small intestine: implications for function. Am J Physiol 1989; 256: 966–74. 
17. Баранская Е.К., Шульпекова Ю.О. Значение опиоидной системы кишечника и способы лекарственного воздействия на нее. Гастроэнтерология (Прил. к журн. Consilium Medicum). 2010; 1: 44–8. / Baranskaya E.K., Shulpekova Yu.O. Znachenie opioidnoj sistemy kishechnika i sposoby lekarstvennogo vozdejstviya na nee. Gastroenterology (Suppl. Consilium Medicum). 2010; 1: 44–8. [in Russian]
18. Белоусова Е.А., Булгаков С.А. Лекарственные средства – лиганды опиатных рецепторов и их применение в гастроэнтерологии. Фарматека. 2011; 2 (215): 26–31. / Belousova E.A., Bulgakov S.A. Lekarstvennye sredstva – ligandy opiatnyh receptorov i ih primenenie v gastroenterologii. Farmateka. 2011; 2 (215): 26–31. [in Russian]
19. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res 1997; 25 (5): 225–46.
20. Zhong YQ, Zhu J, Guo JN et al. A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome. Zhonghua Nei Ke Za Zhi 2007; 46 (11): 899–02.
21. Минушкин О.Н. Сочетанные функциональные расстройства ЖКТ. Их диагностика и лечебные подходы. Мед. совет. 2015; 13: 20–5. / Minushkin O.N. Sochetannye funkcionalnye rasstrojstva ZhKT. Ih diagnostika i lechebnye podhody. Med. sovet. 2015; 13: 20–5. [in Russian]
22. Трухан Д.И., Гришечкина И.А., Быховцев Н.А. Тримебутин в лечении синдрома раздраженного кишечника и других функциональных гастроинтестинальных расстройств. Мед. совет. 2016; 19. / Truhan D.I., Grishechkina I.A., Byhovcev N.A. Trimebutin v lechenii sindroma razdrazhennogo kishechnika i drugih funkcionalnyh gastrointestinalnyh rasstrojstv. Med. sovet. 2016; 19. [in Russian]
23. Бородулина Е.В., Мареев И.В., Колокольцова М.Ю и др. Сравнительная эффективность препаратов Необутин® Ретард, таблетки пролонгированного действия, покрытые пленочной оболочкой, 300 мг, и Тримедат®, таблетки 200 мг, у больных синдромом раздраженного кишечника. Фарматека. 2017; s5. / Borodulina E.V., Mareev I.V., Kolokolcova M.Yu i dr. Sravnitelnaya effektivnost preparatov Neobutin® Retard, tabletki prolongirovannogo dejstviya, pokrytye plenochnoj obolochkoj, 300 mg, i Trimedat®, tabletki 200 mg, u bolnyh sindromom razdrazhennogo kishechnika. Farmateka. 2017; s5. [in Russian]

________________________________________________

1. Samsonov A.A., Karaulov S.A., Uliankina E.V., Yashina A.V. Crossing the clinical symptoms of functional dyspepsia and irritable bowel syndrome, and their dynamics in the combined therapy prokinetic and probiotics. Consilium Medicum. 2015; 17 (8): 51–4. [in Russian]
2. Maev I.V., Cheremushkin S.V., Kucheryavyj Yu.A., Cheremushkina N.V. Algoritm vedeniya pacientov s sindromom razdrazhennogo kishechnika. Rimskie kriterii IV. RMZh. 2017; 10: 718–22. [in Russian]
3. Stanghellini V, Chan FK, Hasler WL et al. Gastroduodenal Disorders. Gastroenterology 2016; 150 (6): 1380–92.
4. Maev I.V., Andreev D.N., Dicheva D.T. i dr. Funktsional'naya dispepsiya: sovremennoe sostoyanie problemy. Med. vestn. MVD. 2013; 4: 38–45. [in Russian]
5. Maev I.V., Dicheva D.T., Shcheglanova M.P. et al. Functional dyspepsia in the context of the 2016 Rome IV updates. Consilium Medicum. Gastroenterology (Suppl.). 2016; 2: 5–10. [in Russian]
6. Persson R, Wensaas K-A, Hanevik K et al. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. BMC Gastroenterol 2015; 15: 66.
7. Perveen I, Rahman MM, Saha M et al. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol 2014; 33 (3): 265–73. DOI: 10.1007/s12664-014-0447-1
8. Symptom overlaps between functional heartburn, functional dyspepsia, and irritable bowel syndrome. Da Xue Xue Bao Yi Xue Ban. 2014; 45 (3): 489–92.
9. Kumagai H, Yokoyama K, Imagawa T, Yamagata T. Functional dyspepsia and irritable bowel syndrome in teenagers: Internet survey. Pediatr Int 2016; 58 (8): 714–20. DOI: 10.1111/ped.12884
10. Miwa H. Why dyspepsia can occur without organic disease: pathogenesis and management of functional dyspepsia. J Gastroenterol 2012; 47: 862–71.
11. Camilleri M, Tack JF. Current medical treatments of dyspepsia and irritable bowel syndrome. Gastroenterol Clin North Am 2010; 39: 481–93.
12. Maev I.V., Samsonov A.A., Andreev D.N. Sovremennyi algoritm vedeniya patsientov s sindromom khronicheskogo zapora s pozitsii vnedreniya novykh farmakologicheskikh preparatov. Farmateka. 2012; 13: 37–43. [in Russian]
13. Kucheryavyj Yu.A., Andreev D.N. Perspektivy lecheniya kislotozavisimyh zabolevanij. Klin. perspektivy gastroenterologii, gepatologii. 2014; 2: 15–24. [in Russian]
14. Garros A, Mion F, Marjoux S et al. Factors associated with nonresponse to proton pump inhibitors therapy in patients referred for esophageal pH-impedance monitoring. Dis Esophagus 2015.
15. Bitar KN, Makhlouf GM. Selective presence of opiate receptors on intestinal circular muscle cells. Life Sci 1985; 37: 1545–50.
16. Allescher HD, Ahmad S, Kostka P et al. Distribution of opioid receptors in canine small intestine: implications for function. Am J Physiol 1989; 256: 966–74. 
17. Baranskaya E.K., Shulpekova Yu.O. Znachenie opioidnoj sistemy kishechnika i sposoby lekarstvennogo vozdejstviya na nee. Gastroenterology (Suppl. Consilium Medicum). 2010; 1: 44–8. [in Russian]
18. Belousova E.A., Bulgakov S.A. Lekarstvennye sredstva – ligandy opiatnyh receptorov i ih primenenie v gastroenterologii. Farmateka. 2011; 2 (215): 26–31. [in Russian]
19. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res 1997; 25 (5): 225–46.
20. Zhong YQ, Zhu J, Guo JN et al. A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome. Zhonghua Nei Ke Za Zhi 2007; 46 (11): 899–02.
21. Minushkin O.N. Sochetannye funkcionalnye rasstrojstva ZhKT. Ih diagnostika i lechebnye podhody. Med. sovet. 2015; 13: 20–5. [in Russian]
22. Truhan D.I., Grishechkina I.A., Byhovcev N.A. Trimebutin v lechenii sindroma razdrazhennogo kishechnika i drugih funkcionalnyh gastrointestinalnyh rasstrojstv. Med. sovet. 2016; 19. [in Russian]
23. Borodulina E.V., Mareev I.V., Kolokolcova M.Yu i dr. Sravnitelnaya effektivnost preparatov Neobutin® Retard, tabletki prolongirovannogo dejstviya, pokrytye plenochnoj obolochkoj, 300 mg, i Trimedat®, tabletki 200 mg, u bolnyh sindromom razdrazhennogo kishechnika. Farmateka. 2017; s5. [in Russian]

И.В.Маев, А.А.Самсонов*, А.В.Семенова, Е.И.Кузнецова, Д.Н.Андреев, Е.Г.Лобанова

________________________________________________

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*aleksey.samsonov@gmail.com